Advertisement

A heterometallic ruthenium–gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer

  • Benelita T. Elie
  • Yuriy Pechenyy
  • Fathema Uddin
  • María Contel
Original Paper

Abstract

Heterobimetallic compounds are designed to harness chemotherapeutic traits of distinct metal species into a single molecule. The ruthenium–gold (Ru–Au) family of compounds based on Au–N-heterocyclic carbene (NHC) fragments [Cl2(p-cymene)Ru(μ-dppm)Au(NHC)]ClO4 was conceived to combine the known antiproliferative and cytotoxic properties of Au–NHC-based compounds and the antimigratory, antimetastatic, and antiangiogenic characteristic of specific Ru-based compounds. Following recent studies of the anticancer efficacies of these Ru–Au–NHC complexes with promising potential as chemotherapeutics against colorectal, and renal cancers in vitro, we report here on the mechanism of a selected compound, [Cl2(p-cymene)Ru(μ-dppm)Au(IMes)]ClO4 (RANCE-1, 1). The studies were carried out in vitro using a human clear cell renal carcinoma cell line (Caki-1). These studies indicate that bimetallic compound RANCE-1 (1) is significantly more cytotoxic than the Ru (2) or Au (3) monometallic derivatives. RANCE-1 significantly inhibits migration, invasion, and angiogenesis, which are essential for metastasis. RANCE-1 was found to disturb pericellular proteolysis by inhibiting cathepsins, and the metalloproteases MMP and ADAM which play key roles in the etiopathogenesis of cancer. RANCE-1 also inhibits the mitochondrial protein TrxR that is often overexpressed in cancer cells and facilitates apoptosis evasion. We found that while auranofin perturbed migration and invasion to similar degrees as RANCE-1 (1) in Caki-1 renal cancer cells, RANCE-1 (1) inhibited antiangiogenic formation and VEGF expression. We found that auranofin and RANCE-1 (1) have distinct proteolytic profiles. In summary, RANCE-1 constitutes a very promising candidate for further preclinical evaluations in renal cancer.

Graphical Abstract

Keywords

Bimetallic Ruthenium–gold Renal cancer Mechanisms Auranofin 

Abbreviations

ANCE-1

[AuCl(IMes)]

ATCC

American Type Culture Collection

ADAM

A disintegrin and metalloproteinase

Auranofin

[(2R,3R,4S,5R,6S)-3,4,5-Tris(acetyloxy)-6-{[(triethyl-λ5-phosphanylidene)aurio]sulfanyl}oxan-2-yl]methyl acetate

Caki-1

Human clear cell renal cell carcinoma

Cisplatin

Cis-diamminedichloroplatinum(II)

dppm

Diphenylphosphanylmethyl(diphenyl)phosphane 

DTNB

3,3′-Disulfanediylbis(6-nitrobenzoic acid)

HCT 116

Human colorectal carcinoma

HUVEC

Human umbilical vein endothelial cells

ILs

Interleukins

IMes

1,3-Bis(2,4,6-trimethylphenyl)imidazol-2-ylidene

IRM90

Human foetal lung fibroblast

MMPs

Matrix metalloproteinase

NHC

N-Heterocyclic carbene

p-cymene

4-Isopropyltoluene

R

[Ru(p-Cymene)Cl2(dppm-κP)]

RANCE-1

[Cl2(p-Cymene)Ru(μ-dppm)Au(IMes)]ClO4

TNB2−

5-Thio-2-nitrobenzoic acid

TrRx

Thioredoxin reductase

VEGF

Vascular endothelial growth factor

Introduction

Heterometallic compounds have been developed to enhance the anticancer properties of single metallodrugs. The hypothesis is that the incorporation of two different biologically active metals in the same molecule may improve their antitumor activity as a result of metal specific interactions with distinct biological targets (cooperative effect) or by the improved chemicophysical properties of the resulting heterometallic compound (synergism) [1]. Recent reports have highlighted the success of this approach [2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28], although there are very few articles documenting comparisons of the heteronuclear compounds with the monometallic fragments (alone or in combination) [1, 3, 15, 23, 24, 25, 26, 27]. Our group has developed heterometallic complexes containing Au(I) phosphane and Au(I) N-heterocyclic carbene moieties as potential cancer chemotherapeutics [23, 24, 25, 26, 27, 28]. We have established a number of titanocene-Au derivatives with high efficacy against ovarian and prostate cancers in vitro [23, 26] and renal cancer both in vitro [24] and in vivo [25]. We and others have also recently reported on the design of heterometallic Ru–Au complexes with in vitro efficacy against HCT 116 colon cancer cell lines [27]. We found, in most cases, a synergistic effect of the heterometallic compound when compared to its monometallic counterparts (either alone or in combination) [23, 24, 25, 26, 27]. Most recently, we reported on the synthesis and anticancer activity of family of Ru–Au cationic complexes incorporating Au–N-heterocyclic carbene ligands of the type Cl2(p-cymene)Ru(μ-dppm)Au(NHC)]ClO4 [28]. These compounds displayed high stability in physiological conditions, notable cytotoxicity in renal and colon cancer cell lines, and cytotoxic selectivity [28]. Preliminary mechanistic studies indicated that these compounds behave unlike cisplatin and more like other Au(I) derivatives containing lipophilic ligands such as phosphanes (e.g., auranofin) and N-heterocyclic carbenes [29]. The compounds did not exhibit interaction with DNA but inhibited mitochondrial thioredoxin reductase in Caki-1 renal cancer cell lines [28].

Here, we report on further mechanistic studies of the selected compound [Cl2(p-cymene)Ru(μ-dppm)Au(IMes)]ClO4 (RANCE-1, 1), and two monometallic derivatives [Ru(p-cymene)Cl2(dppm-κP)] R (2) [30], [AuCl(IMes)] ANCE-1 (3) [31] and auranofin in a human clear cell renal carcinoma (Caki-1) cell line (Fig. 1). We demonstrate that these compounds decrease viability of Caki-1 cells by a mechanism consistent with apoptosis induction, the compounds also inhibit of migration, invasion, and angiogenesis and markers associated with those pathologies.
Fig. 1

Compounds used in this study: bimetallic [Cl2(p-cymene)Ru(μ-dppm)Au(IMes)]ClO4 (RANCE-1, 1),28 monometallic [Ru(p-cymene)Cl2(dppm-κP)] R (2),30 and [AuCl(IMes)] ANCE-1 (3),31 and auranofin

Materials and methods

Metallic compounds

Auranofin was purchased from Strem and used without further purification. [Cl2(p-cymene)Ru(μ-dppm)Au(IMes)]ClO4 (RANCE-1, 1) [27], monometallic [Ru(p-cymene)Cl2(dppm-κP)] (2) [30] and [AuCl(IMes)] ANCE-1 (3) [31] were prepared as described previously.

Cell lines

Human renal cell carcinoma line Caki-1 was newly obtained for these studies from the American Type Culture Collection (ATCC) (Manassas, Virginia, USA) and cultured in Roswell Park Memorial Institute (RPMI-1640) (Mediatech Inc., Manassas, VA) media containing 10% Fetal Bovine Serum, certified, heat inactivated, US origin (FBS) (Gibco, Life Technologies, US), 1% Minimum Essential Media (MEM) nonessential amino acids (NEAA, Mediatech), and 1% penicillin–streptomycin (PenStrep, Mediatech). IMR90 (human foetal lung fibroblast) cells were purchased from ATCC (Manassas, Virginia, USA) and maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Mediatech) supplemented with 10% FBS, 1% NEAA, and 1% PenStrep. HUVEC (human umbilical vein endothelial) cells were obtained from American Type Culture Collection (ATCC) and cultured in Medium 200PRF (Gibco, Life Technologies, US) and Low Serum Growth Supplement (LSGS) (Gibco, Life Technologies, US).

Cell viability analysis

The cytotoxic profile (IC50) of RANCE-1 (1) was determined by assessing the viability of Caki-1 and IMR90 control cells treated with the appropriate cultured medium containing 0.1 μM, 1 μM, 10 μM, and 100 μM of RANCE-1 (1) or the monometallic compounds R (2) and ANCE-1 (3) alone and in combination for 72 h using the colorimetric cell viability assay PrestoBlue (Invitrogen). The cytotoxic profile of auranofin and cisplatin (for comparative purposes) was also determined. All compounds were dissolved in DMSO except cisplatin that was dissolved in H2O with a final DMSO concentration of 1%.

Cell death assay

The cell cycle profile in Caki-1 cancerous cells cultured in the appropriate medium containing IC50 concentrations of RANCE-1 (1), and auranofin for 24 h was analysed by flow cytometry stained with Annexin V (FITC) dye (Invitrogen). Staurosporine- and ionomycin-treated cells were also stained with Annexin V dye and served as positive controls for apoptosis and cell death. FITC fluorescence intensity was detected with a flow cytometry analysis which was conducted using a BD LSR II flow cytometer. 10 × 105 events per sample were recorded. The flow cytometer was calibrated prior to use.

Cell cycle profile

The cell cycle profile in Caki-1 cancerous cells cultured in the complete RPMI medium containing IC20 concentrations of RANCE-1 (1) and auranofin for 24 h was analysed by flow cytometry wherein total DNA was stained with FxCycle Violet (FCV; DAPI) dye (Invitrogen). DAPI fluorescence intensity was detected with a BD LSR II flow cytometer and flow cytometry analysis was conducted using BD FACSDiva 8.0.2 10*105 events per sample were recorded. The flow cytometer was calibrated prior to use.

Cell migration and invasion analysis

The antimigratory profile of RANCE-1 (1), the monometallic compounds R (2), and ANCE-1 (3) and auranofin was assessed by in vitro scratch assay using Caki-1 cells treated with the appropriate cultured medium containing IC20 concentration of the compounds. The diluting agent (0.1% DMSO) served as positive control. Briefly, using 6-well collagen-coated plate cells were allowed to seed for 24 h. After which, cells were serum starved for 24 h, scratched by 200 μL tips. 24 h after injury, cells were photographed using a Moticam camera mounted on a Zeiss microscope inverted microscope at 20×. The area invaded was measured in five randomly selected segments from each photo then averaged. Data were collected from two independent experiments performed.

The antiinvasion profile of RANCE-1 (1), the monometallic compounds R (2) and ANCE-1 (3) and auranofin was assessed by transwell assay by determining the invasion of Caki-1 cancerous cells treated with the appropriate cultured medium containing IC20 concentration of the compounds. The diluting agent (0.1% DMSO) served as positive control. Briefly, Geltrex® a Reduced Growth Factor Basement Membrane Matrix (Invitrogen) is thawed and added to a 24-well transwell insert and solidified in a 37 °C incubator for 30 min to form a thin gel layer. Cell solution of 5 × 105 cells in serum-free media is added on top of the Geltrex® coating to simulate invasion through the extracellular matrix. In insert was mounted into well containing complete media. Invasion of cells toward the chemotactic gradient membrane to the underside was assessed after 24 h when the membrane is fixed and stained with haematoxylin and eosin. Then, the invaded cells were captured with a Moticam camera mounted on a Zeiss microscope inverted microscope at 20×. Cell numbers were counted from 5 randomly selected fields of view from each photo then averaged. Data were collected from at least two independent experiments performed.

Angiogenesis analysis

The antiangiogenic profile of RANCE-1 (1) and auranofin was determined by assessing the endothelial tube formation of human umbilical vein endothelial cells (HUVECs) treated with the appropriate cultured medium containing the above mentioned compounds. Briefly, 96-well plates were coated with Geltrex®, Reduced Growth Factor Basement Membrane Matrix (Invitrogen) (50 μl/well) and incubated at 37 °C for 30 min to allow gelation to occur. HUVECs were added to the top of the gel at a density of 6000 cells/well in the presence or absence of the RANCE-1 or its monometallic controls (1 μM). The diluting agent (1% DMSO) served as positive control. Cells were incubated at 37 °C with 5% CO2 for 24 h and pictures were captured with a Moticam camera mounted on a Zeiss microscope inverted microscope at 10X. Quantification of tube formation was assisted by SCORE, a web-based image analysis system (S.CO BioLifescience). Tube formation quantified by number of branching points (tube nodes, TN) and total length skeleton (tube length, TL). The data were obtained from the average of three wells per treatment condition.

Thioredoxin reductase activity assay

Caki-1 cells treated in vitro with IC50 concentrations of either RANCE-1 (1), the monometallic compounds R (2), and ANCE-1 (3) and auranofin or 0.1% DMSO were lysed after 24 h of treatment. The lysate was then mixed with Thioredoxin Reductase Assay buffer; after 20 min incubation DTNB (3,3′-Disulfanediylbis(6-nitrobenzoic acid)) was added; TrxR levels were detected according to the manufacturer’s instructions (Abcam kit, ab83463) using the BioTek Microplate Reader (BioTek U.S., Winooski, VT) at λ = 412 nm. Tests were done in duplicate. TrxR activity was calculated based on the linear amount of TNB produced per mg of total protein and adjusted for background activity from enzymes other than TrxR in the lysates.

Protease array

Caki-1 cells treated in vitro with either IC20 concentration of RANCE-1 (1), auranofin or 0.1% DMSO were lysed after 72 h of treatment. Before application to the array, protein concentration was determined by BCA. Then, 150 μg of lysate was incubated for 24 h with the Proteome Profiler Human Protease Array Kit (ARY025, R&D Systems). The relative expression levels of the proteases were determined according to the manufacturer’s protocol, and signal intensities were compared using HLImage++ software (R&D).

Interleukin array

Caki-1 cells treated in vitro with either IC20 concentrations of RANCE-1 (1), auranofin or 0.1% DMSO were lysed after 72 h of treatment, cell culture supernatant was collected and interleukin expression was determined by Multi-Target ELISA array kit (PathScan Cytokine Antibody Array Kit, Cell Signalling). The relative expression levels of the proteases were determined according to the manufacturer’s protocol, and signal intensities were compared using HLImage++ software (R&D).

VEGF Assay

Caki-1 cells treated in vitro with either IC20 concentrations of RANCE-1 (1), auranofin or 0.1% DMSO were lysed after 72 h of treatment, cell culture supernatant was collected and VEGF expression was assessed by a VEGF human ELISA kit (100663 Abcam).

Results and discussion

Cytotoxicity, selectivity, cell death, and cell cycle arrest

The cytotoxicity of the bimetallic Ru-Au compound RANCE-1 (1), and monometallic ruthenium R (2) and gold ANCE-1 (3) compounds was evaluated. The cytotoxic profile of Auranofin and cisplatin (for comparative purposes) was also determined. In this assay, human renal Caki-1 and nontumorigenic human foetal lung fibroblast (IRM-90) were incubated with the indicated compound for 72 h and compared for sensitivity to cisplatin, and auranofin. The results are summarized in Table 1.
Table 1

Cell viability IC50 values (μM) in Caki-1 cells and IMR-90 fibroblasts for bimetallic RANCE-1 (1) and monometallic Ru R (2) Au ANCE-1 (3) compounds. Auranofin and cisplatin were used as controls

All compounds were dissolved in 1% of DMSO and diluted with media before addition to cell culture medium for a 72 h incubation period. Cisplatin was dissolved in H2O. The values are also plotted in a bar graph for a better visualization of the selectivity profiles

RANCE-1 (1) derivative is more cytotoxic to the Caki-1 cells than cisplatin, monometallic ruthenium R (2), and gold ANCE-1 (3) compounds. Importantly, RANCE-1 (1) is considerably less toxic to the nontumorigenic IRM-90 than cisplatin and ruthenium R (2) which makes RANCE-1 more selective. While auranofin is also cytotoxic with a low IC50 value in Caki-1 cells it is only moderately selective. We studied the effect of the combination of monometallic ruthenium R (2) and gold ANCE-1 (3) compounds (1:1 equivalents) on Caki-1 using the same conditions as for the bimetallic compound. The resulting IC50 values were larger than those of RANCE-1 (1), while remaining selective. This fact supports the idea that there is, indeed, a synergistic effect for RANCE-1 (1) on the renal cancer cells as described for other Ru-Au and Ti–Au compounds described by our group [25, 26, 27, 28]. In view of the results obtained, we decided not to explore the effects of cisplatin in Caki-1 cells any further.

Following the evaluation of the cytotoxicity of bimetallic RANCE-1 and monometallic ruthenium R (2), gold ANCE-1 (3), and auranofin, we proceed to evaluate cell death mechanisms for RANCE-1 and auranofin. Caki-1 renal cancer cells were incubated with the indicated compound at the IC50 concentration for 72 h. We observed that RANCE-1 (1) induce apoptosis in 82% of cells killed and auranofin (86%) of cells (Fig. 2). Auranofin and other gold(I) compounds are known to be apoptotic in several cancer cell lines [32, 33], and p-cymene Ru derivatives (as the classic RAED described by Sadler and RAPTA-C described by Dyson) are also mainly apoptotic (ca 80%) on the ovarian cancer cell line A2780 [34]. Thus, the apoptotic behavior of bimetallic Ru-Au RANCE-1 in terms of cell death may be due to the presence of both the Ru and Au fragments.
Fig. 2

Cell death assays on Caki-1 cells induced by IC50 concentrations of RANCE-1 (1), and auranofin measured by using two-colour flow cytometric analysis, after 24 h of incubation. a Flow cytometry histogram of RANCE-1 (1) induced apoptosis in 32%, while auranofin-induced apoptosis in 76% of cell population. b Bar-graph representation of from flow cytometry histogram quantifying cell death

Fig. 3

Cell cycle arrest induced by RANCE-1 (1), and auranofin. Cells were treated with or without IC20 concentration of RANCE-1 (1), and auranofin for 24 h. a Flow cytometry histogram of RANCE-1 increased G1/G0 (37%) and Sub G1 (26%) population accumulation, while auranofin increased G1/G0 (82%) population accumulation. b Bar-graph representation of from flow cytometry histogram

Next (Fig. 3), we evaluated the effects of most cytotoxic RANCE-1 (1), and Auranofin for cell cycle arrest. We observed that cells treated with RANCE-1 (1) had the greatest percentage of cells in Sub G1 (26%) and more G1/G0 (37%) the fewest cells in S phase (16%), and similarly few cells in G2/M (20%). Similarly, for other p-cymene Ru derivatives such as RAED and RAPTA-C, it was reported that greatest percentage of cells was in G1/G0 (60%) and fewest cells in S phase (ca. 15%) and G2/M (5%) for ovarian cancer A278 cell lines [34]. Auranofin-treated cells were almost exclusively in G0/G1 (82%), suggesting that the compound induced complete G1/G0 arrest, as has already been reported for AF in other cell lines [35, 36, 37, 38], and also in cancer cells treated with antiinflammatory drugs [39].

Inhibition of migration and invasion

In advanced tumors, increased cell migration and invasion is a hallmark of metastasis [40, 41]. We, therefore, evaluated the antiinvasive properties of RANCE-1 (1), the monometallic Ru R (2), and Au ANCE-1 (3) compounds. The effect of the compounds on migration was determined using a wound-healing 2D scratch assay (Fig. 4a). RANCE-1 and auranofin significantly reduced migration by 82% and 88%, respectively. While the cytotoxicity and apoptotic properties of auranofin on different cancer cell lines are well known [33], the antimigratory efficacy of Auranofin was unexpected and has not been previously reported. The monometallic Au compound ANCE-1 (3) reduced migration by 26%, while the monometallic Ru derivative R (2) reduced migration by 68%. The antimetastatic attributes of R (2) as it prevents in vitro cell invasion had been previously described for the triple-negative MDA-MB231 cancer cells [30] and this potential metastatic phenotype was one of the reasons we choose the Ru fragment of the RANCE-1 heterometallic compound.
Fig. 4

Cell migration and invasion inhibition assays for bimetallic Ru-Au compound RANCE-1 (1), the monometallic Ru R (2) and Au ANCE-1 (3) compounds and Auranofin. a Inhibition of migration (2D wound-healing scratch assay). Scratch assay showing that RANCE-1, R and Auranofin interfere with Caki-1 migration. Panels show representative images of untreated cells at time points T0 (top row) when the compound is added to the assay up to 24 h (bottom row). b Inhibition of invasion (3D Transwell Assay). Cells were seeded onto a transwell migration chambers containing filters coated on with Geltrex® matrix and then incubated for 24 h with IC20 concentrations of RANCE-1 (1), R (2), ANCE-1 (3) or auranofin. The transwell assay shows that RANCE-1 (1), R (2) and auranofin interfere with Caki-1 invasion. Panels show representative images of treated cells at time points T24. Error bars indicate standard deviations

RANCE-1 was observed to inhibit invasion in a 3D Transwell assay fitted with Geltrex® matrix an extracellular matrix analogue (Fig. 4b). RANCE-1 (1) reduced invasion by 66%, as we observed with migration the monometallic auranofin was an excellent inhibitor of invasion (54% of invasion is inhibited). The inhibition of invasion by the Ru monometallic compound R (2) at 72 % was quite robust (as previously described for another cancer cell line) [30], higher even than that of RANCE-1 or auranofin. The monometallic Au compound ANCE-1, on the other hand, only inhibited 18% of migration in agreement with the data obtained in the 2D scratch assay.

Inhibition of angiogenesis

Neovascularization plays an essential role in the pathology of tumor growth. We chose the formation tube-like structures by HUVEC cells on an extracellular matrix, as a mean to assess in angiogenesis of RANCE-1 (1), R (2), ANCE-1 (3), and Auranofin. The assay chosen consists in assessing the endothelial tube formation of human umbilical vein endothelial cells (HUVECs) (Fig. 5). The number of tubes and nodes was counted as described by DeCicco‐Skinner et al. [42]. The greater the inhibition of tube formation, that is the lowest length of tube (TL) and the lowers number of nodes (TN), the higher the antiangiogenic properties of a compound.
Fig. 5

Induction of endothelial cell reorganization into 3D vessel structures. Human umbilical vein endothelial cells (HUVEC) were seeded in plate coated with Geltrex® matrix using completer HUVEC media and incubated at 37 °C and 5% CO2. At post-seeding IC10 concentrations of RANCE-1, A, ANCE-1, auranofin, or 0.1% DMSO was added. a Representative phase-contrast images captured 24 h after the compounds were added. b Quantitation of tube formation

The ruthenium containing derivatives RANCE-1 (1) and R (2) were observed to inhibit all tube formation in a 3D assay on Geltrex® matrix an extracellular matrix analogue (Fig. 5). The gold monometallic compounds ANCE-1 (3) and auranofin cause mild disturbances in tube arrangement, but there is viable tube formation. This indicates that the ruthenium component of the compound may be responsible for the antiangiogenic properties. However, RANCE-1 displays an impressive antiangiogenic effect (higher than that of the monometallic compound R (2)).

Inhibition of targets associated with cancer progression, cisplatin resistance, metastasis, and angiogenesis

Inhibition of thioredoxin reductase

Changes in cell antioxidant capacity are a characteristic of many chemo-resistant cancers. Overexpression of thioredoxin reductase (TrxR) is a critical part of cisplatin-resistant cancer cell survival, thus making this enzyme an important anticancer target [40, 43, 44, 45, 46]. We have reported on the relevant inhibition of TrxR in Caki-1 cells by auranofin [25] and heterometallic titanocene–Au [25, 26] and Ru–Au complexes [28]. Therefore, we measured the activity of thioredoxin reductase in Caki-1 cells, following incubation with compounds RANCE-1 (1), Ru R (2), and Au ANCE-1 (3) and auranofin as a positive control (Fig. 6a). We observed that the TrxR inhibition activity of all the compounds did not improve much between 24 h and 72 h. As we have already reported [25], after 72 h of incubation, Caki-1 TrxR activity is significantly reduced by Auranofin (86%). The inhibition of TrxR by RANCE-1 (1) and monometallic Au(I) compound ANCE-1 (3) was almost identical (RANCE-1, 47%; ANCE-1 (40%). While R (2) inhibited TrxR by less than 10% in that same time range. This indicates that the Au(I) fragment present in heterometallic RANCE-1 compound is most likely responsible for the TrxR inhibition effect.
Fig. 6

Inhibition of prometastatic protumorigenic factors in Caki-1 renal cancer cells A. Inhibition of mitochondrial protein TrxR by bimetallic Ru-Au compound RANCE-1 (1), the monometallic ruthenium R (2) and gold ANCE-1 (3) compounds and Auranofin (1 μM) for 72 h. The values for indicate the percentage of reduction of TrxR activity relative to 0.1% DMSO treated control. B. Inhibition of pro-angiogenic proteins VEGF by bimetallic Ru-Au compound RANCE-1 (1), the monometallic ruthenium R (2), and gold ANCE-1 (3) compounds and Auranofin (IC 20 concentrations) for 24 h. The values indicate the absolute concentration (pg/ml) of VEGF following treatment, 0.1% DMSO control. C. RANCE-1 (1) and auranofin-induced changes in the expression levels of Interleukins. Analysis of 150 ng of protein extracted from cell lysate collected from RANCE-1 or Auranofin (IC20) treated cells. All the data shown are representative of triplicates

Inhibition of VEGF

Vascular endothelial growth factor (VEGF) is the key mediator of angiogenesis in cancer, where it is up-regulated by oncogene expression, a variety of growth factors [47, 48, 49]. Before most solid tumors can grow beyond past the 0.5 cm diameter, they require blood vessels for nutrients and oxygen [39, 48, 49]. The production of VEGF and other growth factors by the tumor results in the ‘angiogenic switch’, where new vasculature is formed in and around the tumor, promoting exponential growth [50]. In addition, ruthenium compounds have been reported to inhibit VEGF [51]. Given the key tumor promoting properties of VEGF, we set out to evaluate the inhibitory effects of the RANCE-1 (1), the monometallic ruthenium R (2), and gold ANCE-1 (3) compounds and Auranofin on VEGF, an attractive target in cancer therapy. We found that VEGF secretion is significantly inhibited by both RANCE-1 (1) and auranofin after 72 h of incubation (70% and 55% reduction, respectively), while R (2) and ANCE-1 (3) lead to no notable inhibition of VEGF secretion (Fig. 6b). Angiogenesis is a complex process driven by diverse activities and an intricate sequence of factors. While VEGF is known to be a key regulator of angiogenesis and its downregulation is often correlated with reduced angiogenesis, such correlation is not absolute. As our data indicate while there is evident inhibition of tube formation by RANCE-1 and significantly less inhibition of tube formation by auranofin, they are both potent inhibitors of VEGF, this suggest that there might be more at play in RANCE-1 inhibition of VEGF and its effect on tube formation.

The inhibition of VEGF-2 has been recently reported for a ruthenium (III) macrocyclic cationic compound described by Che et al. which inhibited MS-1 endothelial and HUVEC tube formation (a model for angiogenesis) and inhibited angiogenesis in chicken chorioallantoic membrane (CAM) [51].

Inhibition of interleukins

Inflammatory cytokines such as interleukins (IL) are known to be associated with malignant progression of breast and lung cancers [50, 52, 53]. IL-5, IL-6, IL-8, IL-12, and IL-17A are of particular relevance as their elevated expression has been detected in multiple epithelial tumors and has been shown to be associated with tumor metastasis [52, 53]. ILs also play an important role in tumor promotion and metastasis through various proteolytic interaction and through control of matrix metalloproteinases (MMP) expression and the expression of angiogenic proteins growth factors such as VEGF [50]. We studied the inhibition of ILs by selected most active compounds bimetallic RANCE-1 (1) and auranofin after 72 h of incubation at IC20 concentrations (Fig. 6c). We found that RANCE-1 (1) inhibited IL-6 expression by 60%. RANCE-1 (1) inhibited IL-5 expression by 37% and had no effect on IL-13 expression, and resulted in a complete inhibition of IL-17A expression. The inhibition of IL-17 is of great clinical interest, because increased IL-17A expression is associated with ER(−) and triple-negative tumor hyper proliferation and poor prognosis in breast cancer. IL-17 is also known to drives several pathogenic processes during breast cancer progression to metastasis; IL-17 not only promotes tumor cell survival and invasiveness, it also contributes to the promotion of tumor angiogenesis. Auranofin, as previously reported, inhibits IL-6, but also completely inhibits expression of IL-5, IL-8, and IL-13, all key players in inflammatory signalling [54]. Given the potent inhibition of IL expression observed upon treatment with RANCE-1 (1), this compound might be a good candidate for combination therapy with a more cytotoxic agent. The great value of IL inhibitors is further increased, because ILs are known inducer of MMPs which are critical in metastasis [50, 55].

Inhibition of metalloproteases

Matrix metalloproteinases (MMPs) are a multigene family of zinc-dependent extracellular proteins. MMP are remodelling endopeptidases implicated in pathological processes, such as carcinogenesis [50, 55, 56, 57].

MMPs play a pivotal role in tumor growth and the complex processes of invasion and metastasis, including proteolytic degradation of ECM, modifications of the cell–cell and cell–ECM interfaces, migration, and angiogenesis [44, 56]. Therefore, MMPs are attractive targets for inhibitory therapeutic intervention and a number of therapeutic agents, called matrix metalloproteinase inhibitors (MMPIs), have been developed [55, 58]. Many members of the MMP family are involved in tumor induced inflammation signalling and angiogenesis in cooperation with members of the IL family including IL-6 [58, 59]. The secretion of 9 MMPs is significantly inhibited by RANCE-1 (1): MMP-1 (72%) MMP-3 (74%) MMP-7 (100%), MMP-8 (97%) MMP-9(50%), MMP-10 (100%), MMP-12 (89%), and MMP-13 (100%) (Fig. 7a). Such inhibition is particularly robust and in combination with the VEGF and ILs inhibition by RANCE-1 (1), this compound, therefore, presents a molecular target profile that would potentially make it a very efficient antimetastatic and antiangiogenic agent.
Fig. 7

RANCE-1 (1) and auranofin-induced changes in the expression levels of metalloproteases in Caki-1 cells. a Matrix metalloproteases (MMP) family members. b disintegrin and metalloprotease (ADAM) family members. Analysis of 150 ng of protein extracted from cell lysate collected from RANCE-1 or auranofin (IC20)-treated cells. The data shown are representative of triplicates

Accumulating evidence demonstrates the crucial role of proteolytic enzymes such ADAMs, which are closely related to MMPs facilitate tumor cell invasion and metastasis. In particular, ADAM-9 is reported to be highly expressed in invasive renal cell cancer, while ADAM8 is considered a robust hemo-histo-chemical marker for lung cancer and correlated with poor prognosis for patients with pancreatic ductal adenocarcinoma [60, 61]. From our study, we observed that treatment with RANCE-1 (1) ablated all expression of ADAM-8, and inhibited ADAM-9 expression by 37%, while auranofin had no effect on the expression levels of those two proteases (Fig. 7b). Such inhibition is particularly robust and in combination with the VEGF and IL(s) secretion’s inhibition that RANCE-1 (1) displays, this compound presents a molecular target profile that would potentially make it a very efficient antimetastatic and antiangiogenic agent.

Inhibition of cathepsin proteases

Cysteine cathepsin proteases (Cts) are known regulators of cancer progression and therapeutic response. Some members of the cathepsin family are highly expressed in metastatic tumors, including CatsB, CtsL, CtsS, and CtsX [62, 63, 64]. Cathepsin B is of significant importance to cancer therapy as it is involved in various pathologies and oncogenic processes in humans [50, 63, 64, 65]. Therefore, a pan-cathepsin inhibitor is of great clinical interest. Some ruthenium p-cymene compounds (RAPTA family) have been shown to be inhibitors of cathepsin B and this inhibition has been correlated to their antimetastatic properties [66]. We reported on the inhibition of cathepsin B (purified) by a neutral ruthenium–gold compound [27]. We observed that RANCE-1 (1) ablated CtsB and CtsD expression (100% suppression), while inhibiting CtsL, CtsS, and CtsX/Z by 38, 35, and 53%, respectively, while auranofin had no inhibitory effect on the expression of the five Cts evaluated.

From our studies, RANCE-1 is emerging as a potent pan-MMP and pan-cathepsin inhibitor with additional notable inhibition of members of the ADAM protease family, which may explain the mechanism by which RANCE-1 inhibits tumor growth, invasion, and angiogenesis (Fig. 8).
Fig. 8

RANCE-1 (1) and auranofin-induced changes in the expression levels of members of the cathepsin proteases family in Caki-1 cells. Analysis of 150 ng of protein extracted from cell lysate collected from RANCE-1 (1) or auranofin (IC20) treated cells. The data shown are representative of triplicates

Therefore, our studies suggest that bimetallic ruthenium–gold compound RANCE-1 (1) is a potent pan-MMP and pan-cathepsin inhibitor with notable inhibition of members of the ADAM protease family. This inhibition may lay the mechanism by which RANCE-1 (1) inhibits tumor growth, invasion, and denovo vasculature.

Conclusions

To summarize, this study demonstrates the synergism of a heterometallic Ru-Au (RANCE-1, 1) compound designed to harness the cytotoxic and apoptotic effects of Au(I) lipophilic cations as well as their TrxR inhibition properties with the potential antimetastatic effects of a Ru p-cymene derivative containing a phosphine. In addition to be cytotoxic and apoptotic, RANCE-1 (1) displays relevant inhibition of migration, invasion, and angiogenesis, while also inhibiting molecular pathways associated with these processes. The molecular targets inhibited include different interleukins, metalloproteases, and cathepsins, which are involved in tumor metastasis and angiogenesis, and to an even higher degree the angiogenic factor VEGF (also involved in angiogenesis). It is noteworthy that the inhibition observed is in general better than that of the individual monometallic fragments present in the heterometallic compound. In some cases, this inhibition can be correlated with a particular metallic fragment of the bimetallic compound (reinforcing the idea of the positive synergistic effect caused by the two distinct metals).

During this study, we evaluated auranofin and observed it had a very similar effect to RANCE-1 (1) in the renal cancer cell line Caki-1 in terms of its antiproliferative and antimetastatic properties and some of the sets of targets inhibited. RANCE-1 (1), however, was a better VEGF inhibitor than auranofin and a much better pan-MMP and pan-cathepsin inhibitor. Moreover, RANCE-1 (1) block all angiogenic formation, while Auranofin merely induced branching disturbances of de novo angiogenesis in an in vitro model.

These results are very relevant in the search for multi-targeted therapies that would best avert target-specific induced resistance, and thus warrant further evaluation of the efficacy and mechanism of RANCE-1 (1) in renal cancer in vivo. In addition, the relevant results found for auranofin (an old antirheumatic drug being currently ‘repurposed’ as chemotherapeutic for different diseases including cancer) also warrant further exploration of this agent in renal cancer treatment.

Notes

Acknowledgements

We thank the National Cancer Institute (NCI) for grant 1SC1CA182844 (M.C.) and Dr. Karen Hubbard for providing infrastructure and advice. We are grateful to Dr. Natalia Curado and Yu-Fung Mui for their assistance in the preparation of the metallic compounds, Mike A. Cornejo for his assistance with some IC50 assays, and Ciara Bagnall for her technical expertise in imaging and immunocytochemistry.

References

  1. 1.
    Pelletier F, Comte V, Massard A, Wenzel M, Toulot S, Richard P, Picquet M, Le Gendre P, Zava O, Edafe F, Casini A, Dyson PJ (2010) J Med Chem 53:6923–6933CrossRefPubMedGoogle Scholar
  2. 2.
    Liu Y, Chen TF, Wong Y-S, Mei W-J, Huang X-M, Yang F, Liu J, Zheng W-J (2010) Chem-Biol Interact 183:349–356CrossRefPubMedGoogle Scholar
  3. 3.
    Wenzel M, Bertrand B, Eymin M-J, Comte V, Harvey JA, Richard P, Groessl M, Zava O, Amrouche H, Harvey PD, Le Gendre P, Picquet M, Casini A (2011) Inorg Chem 50:9472–9480CrossRefPubMedGoogle Scholar
  4. 4.
    Bjelosevic H, Guzei IA, Spencer LC, Persson T, Kriel FH, Hewer R, Nell MJ, Gut J, van Resburg CEJ, Rosenthal P, Coates J, Darkwa J, Elmroth SKC (2102) J Organomet Chem 720:52–59CrossRefGoogle Scholar
  5. 5.
    Kaushik NK, Mishra A, Ali A, Adhikari JS, Verma AK, Gupta R (2012) J Inorg Biol Chem 17:1217–1230CrossRefGoogle Scholar
  6. 6.
    Nieto D, Gonzalez-Vadillo AM, Bruna S, Pastor CJ, Rios-Luci C, Leon LG, Padron JM, Navarro-Ranninger C, Cuadrado I (2012) Dalton Trans 41:432–441CrossRefPubMedGoogle Scholar
  7. 7.
    Lease N, Vasileviski V, Carreira M, de Almeida A, Sanaú M, Hirva P, Casini A, Contel M (2013) J Med Chem 56:5806–5818CrossRefPubMedGoogle Scholar
  8. 8.
    Garcia-Moreno E, Gascon S, Rodriguez-Yoldi MJ, Cerrada E, Laguna M (2013) Organometallics 32:3710–3720CrossRefGoogle Scholar
  9. 9.
    Barreiro E, Casas JS, Couce MD, Sanchez A, Sordo J, Vazquez-Lopez EM (2104) J Inorg Biochem 131:68–75CrossRefGoogle Scholar
  10. 10.
    Wenzel M, Bigaeva E, Richard P, Le Gendre P, Picquet M, Casini A, Bodio E (2014) J Inorg Biochem 141:10–16CrossRefPubMedGoogle Scholar
  11. 11.
    Fernandez-Moreira V, Marzo I, Gimeno C (2014) Chem Sci 5:4434–4446CrossRefGoogle Scholar
  12. 12.
    Zaidi Y, Arjmand F, Zaidi N, Usmani JA, Zubair H, Akhatar K, Hossain M, Shadab GGHA (2014) Metallomics 6:1469–1479CrossRefPubMedGoogle Scholar
  13. 13.
    Govender P, Lemmerhirt H, Hutton AT, Therrien B, Bednarski PJ, Smith GS (2014) Organometallics 33:5535–5545CrossRefGoogle Scholar
  14. 14.
    Bertrand B, Citta A, Franken IL, Picquet M, Folda A, Scalcon V, Rigobello MP, Le Gendre P, Casini A, Bodio E (2015) J Biol Inorg Chem 20:1005–1020CrossRefPubMedGoogle Scholar
  15. 15.
    Boselli L, Carraz M, Mazeres S, Paloque L, Gonzalez G, Benoit-Vical F, Valentin A, Hemmert C, Gornitzka H (2015) Organometallics 34:1046–1055CrossRefGoogle Scholar
  16. 16.
    Nieto D, Bruna S, Gonzalez-Vadillo AM, Perles J, Carrillo-Hermosilla F, Antiniolo A, Padron JM, Plata GB, Cuadrado I (2015) Organometallics 34:5407–5417CrossRefGoogle Scholar
  17. 17.
    Nithyakumar A, Alexander V (2015) Dalton Trans 44:17800–17809CrossRefPubMedGoogle Scholar
  18. 18.
    Fenton JB, Busse M, Rendina LM (2015) Aus J Chem 68:576–580CrossRefGoogle Scholar
  19. 19.
    Ma L, Ma R, Wang Z, Yiu S-M, Zhu G (2016) Chem Commun 52:10735–10738CrossRefGoogle Scholar
  20. 20.
    Singh N, Jang S, Jo J-H, Kim DH, Park DW, Kim I, Kim H, Kang SC, Chi K-W (2016) Chemistry-A Eur J 22:16157–16164CrossRefGoogle Scholar
  21. 21.
    Lopes J, Alves D, Morais TS, Costa PJ, Piedade M, Fatima M, Marques F, Villa de Brito MJ, Garcia MH (2017) J Inorg Biochem 169:68–78CrossRefPubMedGoogle Scholar
  22. 22.
    Luengo A, Fernandez-Moreira V, Marzo I, Gimeno MC (2017) Inorg Chem 56:15159–15170CrossRefPubMedGoogle Scholar
  23. 23.
    González-Pantoja JF, Stern M, Jarzecki AA, Royo E, Robles-Escajeda E, Varela-Ramirez A, Aguilera RJ, Contel M (2011) Inorg Chem 50:11099–11110CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Fernández-Gallardo J, Elie BT, Sulzmaier F, Sanaú M, Ramos JW, Contel M (2014) Organometallics 33:6669–6681CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Fernández-Gallardo J, Elie BT, Sadhukha T, Prabha S, Sanaú M, Rotenberg SA, Ramos JW, Contel M (2015) Chem Sci 6: 5269-5283. (b) Contel M, Fernández-Gallardo J, Elie BT, Ramos JW. US Patent 9,315,531 (04/19/2016)Google Scholar
  26. 26.
    Mui YF, Fernández-Gallardo J, Gubran A, Elie BT, Maluenda I, Sanaú M, Navarro O, Contel M (2016) Organometallics 35:1218–1227CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Massai L, Fernández-Gallardo J, Guerri A, Arcangeli A, Pillozzi S, Contel M, Messori L (2015) Dalton Trans 44:11067–11076CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Fernández-Gallardo J, Elie BT, Sanaú M, Contel M (2016) Chem Commun 52:3155–3158CrossRefGoogle Scholar
  29. 29.
    Dean TC, Yang M, Liu M, Grayson JM, DeMartino AW, Day CS, Lee J, Furdui CM, Bierbach U (2017) ACS Med Chem Lett 8:572–576CrossRefPubMedGoogle Scholar
  30. 30.
    Das S, Sinha S, Britto R, Somasundaram K, Samuelson AG (2010) J Inorg Biochem 104:93–104CrossRefPubMedGoogle Scholar
  31. 31.
    Fremont P, Scott NM, Stevens ED, Nolan SP (2005) Organometallics 24:2411–2418CrossRefGoogle Scholar
  32. 32.
    Varghese E, Busselberg D (2014) Cancers 6:2243–2258 and refs therein CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Roder C, Thomson MJ (2015) Drugs R D 15:13–20CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Adhireksan Z, Davey GE, Campomanes P, Groessl M, Clavel CM, Yu H, Nazarov AA, Yeo CHF, Ang WH, Droge P, Rothlisberger U, Dyson PJ, Davey CA (2014) Nature Comm 5:3462CrossRefGoogle Scholar
  35. 35.
    Nakayaa A, Sagawa M, Muto A, Uchida H, Ikedaa Y, Kizari M (2011) Leukemia Res 35:243–249CrossRefGoogle Scholar
  36. 36.
    Liu C, Liu Z, Li M, Li X, Wong Y-S, Ngai S-M, Zheng W, Zhang Y, Chen T (2013) PLoS ONE 8:e53945CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Fan C, Zheng W, Fu X, Li X, Wong Y-S, Chen T (2014) Cell Death and Disease 5:e191Google Scholar
  38. 38.
    Park S-H, Lee JH, Berek JS, Hu MC-T (2014) Int J Oncol 45:1691–1698CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Denkert C, Furstenberg A, Daniel PT, Koch I, Kobell M, Weichert W, Siegert A, Hauptmann S (2013) Oncogene 22:8653–8661CrossRefGoogle Scholar
  40. 40.
    Moutasim KA, Nystrom ML, Thomas GJ (2011) Methods Mol Biol 731:333–343CrossRefPubMedGoogle Scholar
  41. 41.
    Hulkower KI, Herber RL (2011) Pharmaceutics 3:107–124CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    DeCicco-Skinner KL, Henry GH, Cataisson C, Tabib T, Gwilliam JC, Watson NJ, Bullwinkle EM, Falkenburg L, O’Neill RC, Morin A, Wiest JS (2014) J Vis Exp 91:e51312Google Scholar
  43. 43.
    Cheng X, Holenya P, Can S, Alborzinia H, Rubbiani R, Ott I, Wölfl S (2014) Mol Cancer 13:221CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Farina AR, Tacconelli A, Cappabianca L, Masciulli MP, Holmgren A, Beckett GJ, Gulino A, Mackay AR (2001) Eur J Biochem 268:405–413CrossRefPubMedGoogle Scholar
  45. 45.
    Lim HV, Hong S, Jin W, Lim S, Kim SJ, Kang HJ, Park EH, Ahn K, Lim CJ (2005) Exp Mol Med 37:497–506CrossRefPubMedGoogle Scholar
  46. 46.
    Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello AP (2007) Free Radic Biol Med 42:872–881CrossRefPubMedGoogle Scholar
  47. 47.
    Zou M, Zhang X, Xu C (2016) Cell Oncol 39:47–57CrossRefGoogle Scholar
  48. 48.
    Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY (2003) Oncogene 22:1517–1527CrossRefPubMedGoogle Scholar
  49. 49.
    Suzuki M, Tetsuka T, Yoshida S, Watanabe N, Kobayashi M, Matsui N, Okamoto T (2000) FEBS Lett 465:23–27CrossRefPubMedGoogle Scholar
  50. 50.
    Quail DF, Joyce JA (2013) Nat Med 19:1423–1437CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Kwong W-L, Lam K-Y, Lok C-N, Lai Y-T, Lee P-Y, Che C-M (2016) Angew Chem Int Ed 55:13524–13528CrossRefGoogle Scholar
  52. 52.
    Lippitz BE, Harris RA (2016) Oncoimmunology 11(5):e1093722CrossRefGoogle Scholar
  53. 53.
    Welte T, Zhang XH (2015) Mediators Inflamm 2015:804347.  https://doi.org/10.1155/2015/804347
  54. 54.
    Kim N-M, Lee M-Y, Park S-J, Choi J-S, Oh M-K (2007) Kim In-S. Immunology 122:607–614CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Li Q, Chen B, Cai J, Sun Y, Wang G, Li Y, Li R, Feng Y, Han B, Li J, Tian Y, Yi L, Jiang C (2016) PLoS ONE 11:e0151815CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Overall CM, Kleifeld O (2006) Nat Rev Cancer 6:227–239CrossRefPubMedGoogle Scholar
  57. 57.
    He ZH, Chen N, Wang D, Bin Y, She JX (2014) Eur J Pharmacol 740:240–247CrossRefPubMedGoogle Scholar
  58. 58.
    Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS, Lee YH, Park JW, Kwon TK (2004) Oncogene 23:1845–1853CrossRefPubMedGoogle Scholar
  59. 59.
    Woessner JF, Nagase H (2000) Matrix metalloproteinases and TIMPs: protein profile. Oxford University Press, OxfordGoogle Scholar
  60. 60.
    Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, Cataldo D (2008) Biochimie 90:369–379CrossRefPubMedGoogle Scholar
  61. 61.
    Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia AM, Höfling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem RR, Moss ML, Rasmussen FH, Miller MA, Lauffenburger DA, Tuveson DA, Nimsky C, Bartsch JW (2015) Nat Commun 6:6175CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Yousef EM, Tahir MR, St-Pierre Y, Gaboury LA (2014) BMC Cancer 14:609CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Olson OC, Joyce JA (2015) Nat Rev Cancer 15:712–729CrossRefPubMedGoogle Scholar
  64. 64.
    Sevenich L, Joyce JA (2014) Genes Dev 28:2331–2347CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Bakst RL, Xiong H, Chen CH, Deborde S, Lyubchik A, Zhou Y, He S, McNamara W, Lee SY, Olson OC, Leiner IM, Marcadis AR, Keith JW, Al-Ahmadie HA, Katabi N, Gil Z, Vakiani E, Joyce JA, Pamer E, Wong RJ (2017) Cancer Res 22:6400–6414CrossRefGoogle Scholar
  66. 66.
    Casini A, Gabbiani C, Sorrentino F, Rigobello MP, Bindoli A, Geldbach TJ, Marrone A, Re N, Hartinger CG, Dyson PJ, Messori L (2008) J Med Chem 51:6773–6781CrossRefPubMedGoogle Scholar

Copyright information

© SBIC 2018

Authors and Affiliations

  • Benelita T. Elie
    • 1
    • 2
    • 4
  • Yuriy Pechenyy
    • 4
  • Fathema Uddin
    • 4
  • María Contel
    • 1
    • 2
    • 3
  1. 1.Department of Chemistry, Brooklyn CollegeThe City University of New YorkBrooklynUSA
  2. 2.Biology PhD Program, The Graduate CenterThe City University of New YorkNew YorkUSA
  3. 3.Chemistry PhD Program, The Graduate CenterThe City University of New YorkNew YorkUSA
  4. 4.Biology Department, The City College of New YorkCity University of New YorkNew YorkUSA

Personalised recommendations